BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 18463402)

  • 1. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
    Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
    Garwood ER; Kumar AS; Shim V
    Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
    Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
    Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin use and breast cancer: prospective results from the Women's Health Initiative.
    Cauley JA; McTiernan A; Rodabough RJ; LaCroix A; Bauer DC; Margolis KL; Paskett ED; Vitolins MZ; Furberg CD; Chlebowski RT;
    J Natl Cancer Inst; 2006 May; 98(10):700-7. PubMed ID: 16705124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy.
    Tewari M; Pradhan S; Singh U; Shukla HS
    Breast; 2007 Oct; 16(5):540-5. PubMed ID: 17587581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and breast cancer in postmenopausal women without hormone therapy.
    Eaton M; Eklof J; Beal JR; Sahmoun AE
    Anticancer Res; 2009 Dec; 29(12):5143-8. PubMed ID: 20044629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins and cancer risk.
    Karp I; Behlouli H; Lelorier J; Pilote L
    Am J Med; 2008 Apr; 121(4):302-9. PubMed ID: 18374689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells.
    Mueck AO; Seeger H; Wallwiener D
    Menopause; 2003; 10(4):332-6. PubMed ID: 12851516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
    Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
    Bardia A; Hartmann LC; Vachon CM; Vierkant RA; Wang AH; Olson JE; Sellers TA; Cerhan JR
    Arch Intern Med; 2006 Dec 11-25; 166(22):2478-83. PubMed ID: 17159013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
    Jemal A; Ward E; Thun MJ
    Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
    Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?
    Bird PA; Hill AG; Houssami N
    Ann Surg Oncol; 2008 Jul; 15(7):1983-8. PubMed ID: 18408976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body weight correlates with mortality in early-stage breast cancer.
    Enger SM; Greif JM; Polikoff J; Press M
    Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.